R-548

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameR-548
Drug Alias NameR-548
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK3 inhibitors
TargetsTyrosine-protein kinase JAK3
Therapy Area/IndicationsRejection of organ transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRigel Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRigel Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantation

Other Information

ATC CodeN/A
Related LinksN/A